InMed Pharmaceuticals (INM) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
InMed Pharmaceuticals has appointed Dr. Barry Greenberg, a renowned expert in Alzheimer’s disease, to its Scientific Advisory Board. Dr. Greenberg’s extensive experience will be crucial as the company advances its INM-901 drug candidate towards human trials. This move highlights InMed’s commitment to developing effective therapies for Alzheimer’s disease.
For further insights into INM stock, check out TipRanks’ Stock Analysis page.
